 NEW YORK, Dec. 13, 2020 GLOBE NEWSWIRE -- SELLAS Life Sciences Group, Inc. Nasdaq: SLS SELLAS or the Company, a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it has entered into a share purchase agreement with institutional investors to purchase approximately 16.2 million of its common stock in a registered direct offering at a purchase price of 7.00 per share. 